Direct answer
Prenatal screening estimates the chance of selected conditions; diagnostic testing examines fetal or placental genetic material to determine whether a condition is present. NIPT, combined first-trimester screening, and ultrasound are screening approaches. CVS and amniocentesis obtain samples that laboratories can analyse with tests such as karyotype, chromosomal microarray, targeted gene testing, or exome sequencing.
A low-chance NIPT result substantially reduces the probability of the common trisomies included in that test, but it does not prove that the fetus has no structural, chromosomal, or genetic condition. A high-chance result is also not the same as a diagnosis and generally needs counselling and consideration of confirmatory diagnostic testing.
Screening and sampling are different decisions
NIPT analyses placental DNA fragments circulating in maternal blood. Its performance varies by condition and clinical context. Ultrasound can identify structural findings and markers that may change the interpretation of a screening result. Neither replaces the other.
CVS usually samples placental tissue earlier in pregnancy. Amniocentesis samples amniotic fluid later. The most appropriate procedure depends on gestational age, placental position, the clinical question, the possibility of placental mosaicism, and patient preference after counselling. Procedure-related risks should be discussed using the operator’s current evidence and local pathway rather than a generic internet number.
The laboratory test determines the level of resolution
A sample is only the beginning. Karyotype assesses chromosome number and large structural changes. Chromosomal microarray can identify smaller gains and losses of genetic material. Targeted testing looks for a specific condition suggested by family history or fetal phenotype. Exome sequencing examines many coding regions and may be considered in selected fetuses with structural abnormalities when standard testing has not provided an answer.
Greater resolution does not guarantee certainty. Tests can return a pathogenic finding, a normal result within the method’s limits, a variant of uncertain significance, or an incidental result with implications beyond the immediate pregnancy. Pre-test counselling should explain what results are possible and which findings the patient wishes to receive.
A better decision framework
Start with the question: Is the goal general risk assessment, clarification of an abnormal screen, investigation of a fetal finding, or testing for a known familial condition? Then consider timing, what each result could change, the limitations of the test, procedural risk, turnaround time, and the patient’s values. The technically most extensive test is not automatically the most appropriate first test.
The result decoder
Three kinds of information.
Three different questions.
Select the type of result you are trying to understand. The next step depends on the question—not just the name of the test.
How likely is a particular condition?
Screening puts a pregnancy into a higher- or lower-chance group for the conditions included in that test. NIPT examines DNA fragments in maternal blood, most of which come from the mother and some from the placenta.
What it cannot tell you
A higher-chance result is not a diagnosis. A lower-chance result cannot rule out every chromosome condition, genetic disorder, or structural finding.
The useful next question
Ask which condition the result concerns, what the chance means for your pregnancy, and whether diagnostic testing would answer the question.
What can we see, measure, and follow?
Ultrasound examines fetal anatomy, growth, fluid, and the placenta. Doppler adds information about blood flow. A specialist scan may confirm a finding, change its interpretation, or identify what needs follow-up.
What it cannot tell you
A reassuring scan does not exclude every genetic condition. Some findings develop later, and visibility depends on gestational age, position, and other factors.
The useful next question
Ask whether the finding is isolated, how certain it is, whether additional imaging or genetic testing could help, and when the next assessment should be.
Can a defined condition be identified?
CVS obtains a placental sample; amniocentesis obtains amniotic fluid. The laboratory analysis is a separate choice: chromosome testing, microarray, or selected gene testing answer different questions.
What it cannot tell you
“Diagnostic” does not mean “tests for everything.” A normal result is reassuring only within the scope of the analysis. Uncertain or unexpected findings may require additional counselling.
The useful next question
Before sampling, agree which analysis is planned, the procedure risks, likely result timing, and how each possible result would affect your decisions.
A smaller denominator means a higher chance.
These are arithmetic examples, not a test result or a prediction for your pregnancy. Ask the team to explain your own number in both formats.
Supporting medical reference
NHS — Screening tests in pregnancyThe essential distinctions
Screening, sampling, analysis: three different steps.
A screening result estimates chance. A sample provides material. The laboratory test determines what can be found.
- Screening
NIPT and other screening tests estimate the chance of selected conditions.
- Diagnostic sampling
CVS samples placental tissue; amniocentesis samples amniotic fluid.
- Laboratory analysis
Karyotype, microarray, and sequencing answer different genetic questions. No test detects everything.
Visual decision pathway
Screening and diagnosis are different routes
Start with the clinical question, then choose whether probability or a diagnostic answer is needed.
- QuestionDefine the purpose
General risk assessment, abnormal screening, fetal finding or a known familial condition?
- RouteChoose screening or sampling
Screening changes probability; CVS or amniocentesis obtains material for diagnosis.
- ResolutionSelect the laboratory test
Karyotype, microarray, targeted testing or exome answer different questions.
- MeaningInterpret before acting
Integrate phenotype, test limits, uncertain variants, timing and what the result can change.